Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolutionary Inspired Therapy for Metastatic Fusion Positive Rhabdomyosarcoma
NCT04388839Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2020
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label trial of vincristine sulfate liposome injection, cyclophosphamide, actinomycin D and vinorelbine in rhabdomyosarcoma (RMS), sponsored by Moffitt Cancer Center. Started Dec 2020; status: active, not recruiting.
02
Drugs
vincristine sulfate liposome injectioncyclophosphamideactinomycin Dvinorelbine
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT04388839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388839.